China NMPA grants breakthrough therapy designation for Innovent’s PD-1/IL-2a-bias bispecific antibody fusion protein, IBI363 in melanoma: San Francisco, US Tuesday, April 1, 202 ...
In a report released on March 28, Yang Huang from J.P. Morgan maintained a Buy rating on Innovent Biologics (IVBXF – Research Report), with a ...
SAN FRANCISCO and SUZHOU, China, March 30, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutic ...
Innovent is a leading biotech company in China with strong roots in oncology, anchored by its core PD-1 drug Tyvyt. The price cut for PD-1 drugs has stabilized gradually. Hence, we expect stable ...
First-ever positive profit, entering a new era of growth and global innovation SAN FRANSISCO and SUZHOU, China, March 26, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: ...
Innovent Biologics begins patient dosing in phase 3 study of IBI354 for platinum-resistant ovarian cancer: San Francisco Tuesday, March 25, 2025, 18:00 Hrs [IST] Innovent Biologic ...
Innovent Biologics has dosed the first subject in the randomised Phase III HeriCare-Ovarian01 trial of IBI354 for treating ...
SAN FRANCISCO and SUZHOU, China, March 23, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that ...
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback